Marco Zamparelli-Sanduzzi

Pi, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

Corrigendum to "Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes" [Eur J Cancer (May) (2025) 15:221:115404].

Corrigendum to "Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes" [Eur J Cancer (May) (2025) 15:221:115404].

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 03, 2026

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].

Journal: Journal of hepatology

Published: April 05, 2026

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal: Journal of hematology & oncology

Published: March 25, 2026

Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.

Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.

Journal: Frontiers in immunology

Published: January 29, 2026

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Journal: Alimentary pharmacology & therapeutics

Published: December 08, 2025

BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update.

BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update.

Journal: Journal of hepatology

Published: September 12, 2025

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update.

Journal: Journal of hepatology

Published: September 12, 2025

Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinoma.

Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: August 28, 2025

Akkermansia muciniphila and HCC: A Gut Feeling.

Akkermansia muciniphila and HCC: A Gut Feeling.

Journal: Current oncology (Toronto, Ont.)

Published: August 25, 2025

Corrigendum to" Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes," [Eur J Cancer 2025 May 15:221:115404.].

Corrigendum to" Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes," [Eur J Cancer 2025 May 15:221:115404.].

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 18, 2025

Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.

Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.

Journal: Frontiers in immunology

Published: April 14, 2025

Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Journal: Nature

Published: February 25, 2025

Showing 1-12 of 62

Last Updated: 09/26/2026